Marrone Bio Innovations
Market Cap
US$375.2m
Last Updated
2021/03/08 00:20 UTC
Data Sources
Company Financials +
Executive Summary
Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Marrone Bio Innovations's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MBII is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MBII's weekly volatility (12%) has been stable over the past year.
Market Performance
7 Day Return
-12.3%
MBII
1.7%
US Chemicals
-0.4%
US Market
1 Year Return
117.5%
MBII
38.9%
US Chemicals
36.2%
US Market
Return vs Industry: MBII exceeded the US Chemicals industry which returned 38.9% over the past year.
Return vs Market: MBII exceeded the US Market which returned 36.2% over the past year.
Shareholder returns
| MBII | Industry | Market | |
|---|---|---|---|
| 7 Day | -12.3% | 1.7% | -0.4% |
| 30 Day | -4.7% | 0.7% | -2.9% |
| 90 Day | 77.8% | 5.8% | 5.0% |
| 1 Year | 117.5%117.5% | 42.0%38.9% | 39.1%36.2% |
| 3 Year | 26.6%26.6% | 27.3%7.6% | 48.4%39.0% |
| 5 Year | 94.8%94.8% | 92.2%53.6% | 116.5%92.4% |
Long-Term Price Volatility Vs. Market
How volatile is Marrone Bio Innovations's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?1 month ago | Simply Wall St
Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain2 months ago | Simply Wall St
When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?Valuation
Is Marrone Bio Innovations undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MBII ($2.24) is trading below our estimate of fair value ($6.22)
Significantly Below Fair Value: MBII is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MBII is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.
PE vs Market: MBII is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MBII's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MBII is overvalued based on its PB Ratio (14.8x) compared to the US Chemicals industry average (2.6x).
Next Steps
Future Growth
How is Marrone Bio Innovations forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
59.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBII is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: MBII is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MBII's is expected to become profitable in the next 3 years.
Revenue vs Market: MBII's revenue (27.2% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: MBII's revenue (27.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBII's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Marrone Bio Innovations performed over the past 5 years?
7.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MBII is currently unprofitable.
Growing Profit Margin: MBII is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MBII is unprofitable, but has reduced losses over the past 5 years at a rate of 7.5% per year.
Accelerating Growth: Unable to compare MBII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MBII is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-1.4%).
Return on Equity
High ROE: MBII has a negative Return on Equity (-112.95%), as it is currently unprofitable.
Next Steps
Financial Health
How is Marrone Bio Innovations's financial position?
Financial Position Analysis
Short Term Liabilities: MBII's short term assets ($24.0M) exceed its short term liabilities ($22.9M).
Long Term Liabilities: MBII's short term assets ($24.0M) do not cover its long term liabilities ($26.0M).
Debt to Equity History and Analysis
Debt Level: MBII's debt to equity ratio (108.2%) is considered high.
Reducing Debt: MBII's debt to equity ratio has reduced from 734.5% to 108.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MBII has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MBII has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 18.8% each year.
Next Steps
Dividend
What is Marrone Bio Innovations's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MBII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MBII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MBII's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MBII's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MBII's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Kevin Helash (55 yo)
0.58
Tenure
Mr. Kevin R. Helash serves as Chief Executive Officer and Director at Marrone Bio Innovations, Inc. since August 03, 2020. He had been the Chief Executive Officer of Agrinos AS since November 20, 2017 unti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 15.17yrs | US$894.20k | 1.39% $ 5.2m | |
| Chief Manufacturing Officer | 2.83yrs | US$701.20k | 0.023% $ 85.9k | |
| CEO & Director | 0.58yr | no data | no data | |
| Chief Financial Officer | 0.083yr | no data | no data | |
| Senior VP of R&D and Chief Technical Officer | 4.58yrs | no data | no data | |
| Vice President of Business Development & Investor Relations | no data | no data | no data | |
| Executive VP & General Counsel | 7yrs | US$443.38k | no data | |
| Director of Marketing | no data | no data | no data | |
| Director of National Sales & Account Management | 2.42yrs | no data | no data | |
| Senior VP of Regulatory & Government Affairs and Chief Sustainability Officer | 4.58yrs | no data | no data | |
| Senior Vice President of International Sales | 0.083yr | no data | 0.0028% $ 10.5k |
2.8yrs
Average Tenure
56yo
Average Age
Experienced Management: MBII's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 15.17yrs | US$894.20k | 1.39% $ 5.2m | |
| CEO & Director | 0.58yr | no data | no data | |
| Independent Director | 2.58yrs | US$75.02k | no data | |
| Independent Chairman | 3.08yrs | US$119.30k | 0.0021% $ 7.8k | |
| International Science Advisory Panel Member | no data | no data | no data | |
| Independent Director | 4.83yrs | US$90.80k | 0.029% $ 109.3k | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| International Science Advisory Panel Member | no data | no data | no data | |
| Independent Director | 2.58yrs | US$75.02k | no data |
2.8yrs
Average Tenure
62yo
Average Age
Experienced Board: MBII's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.5%.
Top Shareholders
Company Information
Marrone Bio Innovations, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Marrone Bio Innovations, Inc.
- Ticker: MBII
- Exchange: NasdaqCM
- Founded: 2006
- Industry: Fertilizers and Agricultural Chemicals
- Sector: Materials
- Market Cap: US$375.151m
- Shares outstanding: 167.48m
- Website: https://www.marronebio.com
Number of Employees
Location
- Marrone Bio Innovations, Inc.
- 1540 Drew Avenue
- Davis
- California
- 95618
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MBII | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Aug 2013 |
| 0MB | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Aug 2013 |
Biography
Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally. Its products i...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/08 00:20 |
| End of Day Share Price | 2021/03/05 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.